Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Publication details: 2024; ; ISSN:- 2041-1723
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
| Journal Article | MedStar Authors Catalog | Article | Available | 38730268 |
English